en · de · es
epitalon-notes.peptides1126.com › News › Epitalon Background And Discovery — Reference Sheet

Epitalon Background And Discovery — Reference Sheet

By Editorial Desk · published 2025-12-15 · last reviewed 2026-01-05 · News

If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-05. Numbers and descriptions here follow the published literature rather than marketing material.

Epitalon Background and Discovery

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

Laboratory Handling and Analytical Verification

Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.

Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.

Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four-residue sequence
Molar massAbout 390.35 g/molFree peptide, counter-ion not included
AppearanceWhite to off-white powderLyophilised solid from aqueous solution
Water solubilityFreely solubleShort, polar peptide chain
Common synonymsAEDG; epithaloneCatalogues use the names interchangeably

Epitalon Background and Nomenclature

Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.

The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.

Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.

Related pages on this site

Handling, Storage and Analytical Checks

Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.

Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.

Structure, Naming and Discovery

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Background from the literature

On March 13, 2019, three years after voters narrowly rejected its repeal in the 2016 California Proposition 62, Newsom declared a moratorium on the state's death penalty, preventing any execution in the state as long as he remained governor. The move also led to the withdrawal of the state's current lethal injection protocol and the execution chamber's closure at San Quentin State Prison. In a CBS This Morning interview, Newsom said that the death penalty is "a racist system ... that is perpetuating inequality. It's a system that I cannot in good conscience support." The moratorium granted a temporary reprieve for all 737 inmates on California's death row, then the largest death row in the Western Hemisphere. In January 2022, Newsom directed the state to begin dismantling its death row in San Quentin, to be transformed into a "space for rehabilitation programs", as all the condemned inmates were moving to other prisons that have maximum security facilities. The state's voters upheld capital punishment in 2012 and 2016, agreeing when they did so in 2016 to move the condemned to other prisons. While a 2021 poll by the UC Berkeley Institute of Governmental Studies and co-sponsored by the Los Angeles Times suggested declining support for capital punishment among California's voters, Republican opponents criticized Newsom's moves to halt capital punishment in California as defiance of the will of voters, and capital punishment advocates said they denied closure to murder victims' families.

=== Development of pretargeted imaging === To bypass the problem associated with the prolonged circulation time of radiolabelled antibodies, in the mid-1980s a strategy called pretargeted radioimmunotherapy was developed. In short, this approach contained two important steps: 1. administration of a macromolecular targeting vector (usually antibody-based), and 2. a small radiolabelled molecule, which interacts with the targeting vector. Most importantly the small radiolabelled molecule gets injected after a predetermined lag period after which the macromolecule has had enough time to bind to its target and the residual unbound macromolecule to be cleared out of the system. To ensure sufficient interaction between the two components, suitable modifications with complementary species are required (like bioorthogonal modifications). Pretargeting strategies can lead to an improved imaging contrast, as it combines the high target specificity and affinity of an antibody with the fast pharmacokinetic properties of a small molecule. The concept of pretargeting, although existing for several decades already, was limited to a few distinct classes. Developing chemical reactions that proceed quickly within living systems, without interacting with the large variety of existing functional groups, used to be an inherent difficulty. However, there have been several advancements in this area over the past few years.

=== Lobbying the FDA === In 2011, the FDA made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines. Breakthrough T1D launched a campaign to influence those guidelines to be lenient. After the first closed-loop device was approved in 2016, Breakthrough T1D lobbied insurance companies to cover it. The campaign also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH. The FDA lobbying campaign was part of a gradual realignment of the organization to focus on issues other than helping find a cure for type 1 diabetes, but to help treat and manage the disease. This broadened scope meant that the organization increasingly directed its funds to education and advocacy, along with research funding. This included lobbying insurance companies to pay for CGM devices, educating patients on how to advocate for themselves, and lobbying Congress for more NIH funding.

Sources: en.wikipedia.org

Reference notes

An isopeptide bond is a type of amide bond formed between a carboxyl group of one amino acid and an amino group of another. An isopeptide bond is the linkage between the side chain amino or carboxyl group of one amino acid to the α-carboxyl, α-amino group, or the side chain of another amino acid. In a typical peptide bond, also known as eupeptide bond, the amide bond always forms between the α-carboxyl group of one amino acid and the α-amino group of the second amino acid. Isopeptide bonds are rarer than regular peptide bonds. Isopeptide bonds lead to branching in the primary sequence of a protein. Proteins formed from normal peptide bonds typically have a linear primary sequence. Amide bonds, and thus isopeptide bonds, are stabilized by resonance (electron delocalization) between the carbonyl oxygen, the carbonyl carbon, and the nitrogen atom. The bond strength of an isopeptide bond is similar to that of a peptide due to the similar bonding type. The bond strength of a peptide bond is around 300 kJ/mol, or about 70 kcal/mol. Amino acids such as lysine, glutamic acid, glutamine, aspartic acid, and asparagine can form isopeptide bonds because they all contain an amino or carboxyl group on their side chain. For example, the formation of an isopeptide bond between the sidechains of lysine and glutamine is as follows:

== Sponsored events == Chick-fil-A Classic The Chick-fil-A Classic is a high school basketball tournament held in Columbia, South Carolina, featuring nationally ranked players and teams. The tournament is co-sponsored by the Greater Columbia Educational Advancement Foundation (GCEAF), which provides scholarships to high school seniors in the greater Columbia area. Chick-fil-A Peach Bowl The Chick-fil-A Peach Bowl, first known as the Peach Bowl until 2006 and renamed Chick-fil-A Peach Bowl in 2014, is a college football bowl game played each year in Atlanta, Georgia. Chick-fil-A Kickoff Game The Chick-fil-A Kickoff Game is an annual early-season college football game played at the Mercedes-Benz Stadium in Atlanta, Georgia; before 2017, it was played at the Georgia Dome. It features two highly ranked teams, one of which has always been from the Southeastern Conference. The event was expanded to two games in the 2012 season and again in the 2014 season. It was also two games in 2017. On July 12, 2023, Georgia-based insurance company Aflac, became the new sponsor of the game.

Open to people of Lithuanian descent; sponsors Lithuanian cultural programs, gives aid to widows, and orphans, relief for victims of natural disasters, and awards scholarships. On July 1, 2012, the insurance aspects of the organization passed to the Croatian Fraternal Union. A Special Convention convened on September 22, 2012, authorized the leadership to reconstitute the LAA as a not-for-profit cultural group. Lithuanian Catholic Alliance - Founded in 1886 as the Lithuanian Roman Catholic Alliance of America, adopted its current name in 1975. Headquarters in Wilkes-Barre, Pennsylvania. National convention meets triennially. There were 163 lodges in 1972 and 147 in 1977. 1965 membership was 7,000, which declined to 4,000 in 1979. In 1994 there were 3,069 members, despite membership being opened to non-Catholics. Sponsors Lithuanian cultural activities, cookbooks, films, and radio programs; also sponsors scholarships for members, supports Community Chest, blood donor clinics, Catholic youth programs, youth camps, and Catholic Social Services.

Sources: en.wikipedia.org

Notes from published material

== Structure == Elastic cartilage is histologically similar to hyaline cartilage but contains many yellow elastic fibers lying in a solid matrix. These fibers form bundles that appear dark under a microscope. The elastic fibers require special staining since when it is stained using haematoxylin and eosin (H&E) stain it appears the same as hyaline cartilage. Verhoeff van Geison stains are used (giving the elastic fibers a black color), but aldehyde fuchsin stains, Weigert's elastic stains, and orcein stains also work. These fibers give elastic cartilage great flexibility so that it is able to withstand repeated bending. Similarly to hyaline one or multiple chondrocytes lie between the spaces (or lacunae) in the fibres. The chondrocytes only make up 2% of the tissue's volume. Chondrocytes and the extracellular matrix are contained in an outerlayer named the perichondrium (which is a layer of dense irregular connective tissue that surrounds cartilage which is independent of the joint). It is found in the epiglottis (part of the larynx), and the pinnae (the external ear flaps of many mammals). Elastin fibers stain dark purple/black with Verhoeff's stain. The extracellular matrix contains elastin, fibrillin, glycoproteins, collagen types II, IX, X, and XI, and the proteoglycan aggrecan. the components within the extracellular matrix are produced by the chondroblasts located within the edges of the perichondrium. Elastic fibers within the extracellular matrix are made up of elastin proteins which co-polymerize with fibrillin forming fiber-like elastic chains.

== Research == The antibacterial effect described above (§ Environmental effects) could be applied against multiresistant biotypes in crop bacterial diseases and bacterial aquaculture diseases. In a glucocorticoid receptor-defective zebrafish mutant (Danio rerio) with reduced exploratory behavior, fluoxetine rescued the normal exploratory behavior. This demonstrates relationships between glucocorticoids, fluoxetine, and exploration in this fish. Fluoxetine has an anti-nematode effect. Choy et al., 1999 found some of this effect is due to interference with certain transmembrane proteins.

The process of pasteurizing donkey milk deactivates bacterial and viral contaminants. Donkey milk contains immune-enhancing compounds (in particular lysozyme and lactoferrin) to help protect infants from disease. In addition, the flavour and appearance of donkey milk are attractive to children.

As of 2013, the existence of efficient high-throughput next-generation sequencing technology allows for the identification of cause many different human disorders. Simple Mendelian inheritance has been observed for over 3,000 disorders that have been identified at the Online Mendelian Inheritance in Man database, but complex diseases are more difficult. Association studies have found many individual genetic regions that individually are weakly associated with complex diseases (such as infertility, breast cancer and Alzheimer's disease), rather than a single cause. There are currently many challenges to using genes for diagnosis and treatment, such as how we don't know which genes are important, or how stable the choices an algorithm provides. Genome-wide association studies have successfully identified thousands of common genetic variants for complex diseases and traits; however, these common variants only explain a small fraction of heritability. Rare variants may account for some of the missing heritability. Large-scale whole genome sequencing studies have rapidly sequenced millions of whole genomes, and such studies have identified hundreds of millions of rare variants. Functional annotations predict the effect or function of a genetic variant and help to prioritize rare functional variants, and incorporating these annotations can effectively boost the power of genetic association of rare variants analysis of whole genome sequencing studies.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.

Why is it called epitalon?

The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.

Is epitalon approved for medical use?

No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.

How is epitalon identified in a laboratory?

Reversed-phase high-performance liquid chromatography is run alongside mass spectrometry. The chromatogram separates components and gives a purity figure, while the mass spectrum confirms that the measured molecular mass matches the expected sequence. Neither measurement on its own is treated as sufficient.

Network